In what might prove to be a truly revolutionary medical treatment breakthrough, a new cufflink-sized computer chip that rests on top of the skin can signal new cell growth in any cell type in every part of the body. It can repair injured tissue and revitalize aging tissue to restore function to organs, blood vessels, and nerve cells.
The new device is being called “magical” and “amazing” because it could provide the cure for Alzheimer’s and Parkson’s diseases, damaged kidneys and livers, plus any number of other physical health conditions involving regenerative medicine.
A joint project shared by the Ohio State University Wexner Medical Center and Ohio State College of Engineering have introduced this new healing technology, which they call Tissue Nanotransfection (THT).
THT is a completely noninvasive procedure that does not require making a skin opening, inserting a tube, or performing surgery. Instead, a nanotechnology-based chip is placed directly on the skin of a patient. The computer chip signals the device to emit a small electrical charge that converts a fully matured adult cell from one type to another.
According to Dr. Chandan Sen, project co-leader, one of the study’s authors, and the director of Ohio State’s Center for Regenerative Medicine & Cell-Based Therapies:
“By using our novel nanochip technology, injured or compromised organs can be replaced. We have shown that skin is a fertile land where we can grow the elements of any organ that is declining.”
Wow! Who knew that skin cells could transform into any other kind of tissue cell? This is truly a game-changer for patients suffering from all kinds of medical and health complaints.
The THT system has two main parts: a nanochip, and it’s biological cargo.
The small computer chip uses nanotechnology – “a technology executed on the scale of fewer than 100 nanometers, the goal of which is to control individual atoms and molecules, especially to create computer chips and other microscopic devices” – to carry a genetic load to adult cells in a live body. The nanochip then injects the cargo into the targeted cells.
The biological cargo is “a specific genetic code in the form of DNA or RNA, which, when applied to cells, changes them from their previous structure and function to the structure and functions needed to repair the injury.”
Sending a small electrical charge to the device creates a mild shock that patients barely notice and triggers the cargo delivery.
The study’s other co-leader was L. James Lee, a professor of chemical and biomolecular engineering with the Ohio State College of Engineering, in collaboration with Ohio State’s Nanoscale Science and Engineering Center.
The first test subjects have been mice and pigs. Researchers touched the chip directly on the skin to reprogram the skin cells, transforming them into vascular cells (which are in charge of blood circulation and delivering cell nutrients) in badly injured legs that had very little blood flow – the limbs were atrophied.
The results of this study were astonishing:
“Within one week, active blood vessels appeared in the injured leg, and by the second week, the leg was saved.”
In another experiment, researchers reprogrammed skin cells in the test animal’s living body into nerve cells that were then injected into brain-injured mice to help them recover from strokes.
Dr. Sen said the incredible new THT treatment has an extraordinarily high success rate in clinical trials:
“This is difficult to imagine, but it is achievable, successfully working about 98 percent of the time. With this technology, we can convert skin cells into elements of any organ with just one touch.”
Dr. Sen mentioned how quick, easy, and inexpensive this radical new treatment is:
“This process only takes less than a second and is non-invasive, and then you’re off. The chip does not stay with you, and the reprogramming of the cell starts.”
Just when you thought it couldn’t get any better – it does. Dr. Sen continued, “Our technology keeps the cells in the body under immune surveillance, so immune suppression is not necessary.”
Lee added that “The concept is very simple. As a matter of fact, we were even surprised how it worked so well. In my lab, we have ongoing research trying to understand the mechanism and do even better. So, this is the beginning, more to come.”
More to come indeed. Clinical trials in humans are slated for 2019.